CCL2 and Alzheimer disease: Furthermore, higher plasma MCP-1 levels are associated with faster cognitive decline in AD and MCI patients at the two-year follow-up, and AD and MCI patients with cognitive decline had higher baseline plasma MCP-1 levels.